These findings are in line with previous studies reporting decreased FDG metabolism, increased Aβ deposition, and pathological tau accumulation in these regions in SCD, which closely coincided with the imaging features found in early AD patients (Snitz et al., 2015; Buckley et al., 2017; Vannini et al., 2017). The gene discussed is MAPT; the disease is Alzheimer disease.